Concentra Parent (CON)
Market Price (8/11/2026): $34.095 | Market Cap: $4.3 BilSector: Health Care | Industry: Health Care Services
Concentra Parent (CON)
Market Price (8/11/2026): $34.095Market Cap: $4.3 BilSector: Health CareIndustry: Health Care Services
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 5.4%, FCF Yield is 6.3% Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 15%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 12% Low stock price volatilityVol 12M is 29% Megatrend and thematic driversMegatrends include Digital Health & Telemedicine. Themes include Telehealth Platforms, Health Data Analytics, and AI in Healthcare Management. | Trading close to highsDist 52W High is 0.0%, Dist 3Y High is 0.0% Weak multi-year price returns3Y Excs Rtn is -17% | Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 55% Key risksCON key risks include [1] elevated financial leverage following its recent IPO and acquisitions, Show more. |
| Attractive yieldTotal YieldTotal Yield = Earnings Yield + Dividend Yield, Earnings Yield = Net Income / Market Cap Dividend Yield = Total Dividends / Market Cap is 5.4%, FCF Yield is 6.3% |
| Attractive cash flow generationCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is 15%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is 12% |
| Low stock price volatilityVol 12M is 29% |
| Megatrend and thematic driversMegatrends include Digital Health & Telemedicine. Themes include Telehealth Platforms, Health Data Analytics, and AI in Healthcare Management. |
| Trading close to highsDist 52W High is 0.0%, Dist 3Y High is 0.0% |
| Weak multi-year price returns3Y Excs Rtn is -17% |
| Valuation getting more expensiveP/S 6M Chg %Price/Sales change over 6 months. Declining P/S indicates valuation has become less expensive. is 55% |
| Key risksCON key risks include [1] elevated financial leverage following its recent IPO and acquisitions, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Concentra Parent (CON) stock has gained about 50% since 4/30/2026 because of the following key factors:
1. Exceptional Q2 2026 Financial Performance Exceeded Expectations and Led to Raised Full-Year Guidance. Concentra Parent reported robust results for its fiscal second quarter, which ended June 30, 2026. The company posted revenue of $606.0 million, a 10.0% increase over Q2 2025, surpassing analyst consensus estimates of $591.75 million. Diluted earnings per share (EPS) significantly rose to $0.51, outperforming the $0.42 consensus. Furthermore, Adjusted EBITDA grew 22.5% to $140.9 million, and free cash flow surged 91.6% to $121.0 million. This strong performance, driven by operating leverage and increased patient activity, led the company to raise its full-year 2026 guidance for revenue, Adjusted EBITDA, and free cash flow.
2. Consistent Revenue Growth Driven by Increased Patient Volume and Per-Visit Revenue. The company demonstrated sustained operational strength during fiscal Q2 2026, recording 3.61 million patient visits, with average daily visits increasing 2.6% to 56,421. Revenue per visit also rose 4.6% to $152.67. This combination of higher activity and increased revenue per visit directly contributed to the company's overall revenue growth and improved operating margin, which expanded to approximately 19.0% from 16.3% in Q2 2025.
Show more
Concentra Parent (CON) stock has gained about 50% since 4/30/2026 because of the following key factors:
1. Exceptional Q2 2026 Financial Performance Exceeded Expectations and Led to Raised Full-Year Guidance. Concentra Parent reported robust results for its fiscal second quarter, which ended June 30, 2026. The company posted revenue of $606.0 million, a 10.0% increase over Q2 2025, surpassing analyst consensus estimates of $591.75 million. Diluted earnings per share (EPS) significantly rose to $0.51, outperforming the $0.42 consensus. Furthermore, Adjusted EBITDA grew 22.5% to $140.9 million, and free cash flow surged 91.6% to $121.0 million. This strong performance, driven by operating leverage and increased patient activity, led the company to raise its full-year 2026 guidance for revenue, Adjusted EBITDA, and free cash flow.
2. Consistent Revenue Growth Driven by Increased Patient Volume and Per-Visit Revenue. The company demonstrated sustained operational strength during fiscal Q2 2026, recording 3.61 million patient visits, with average daily visits increasing 2.6% to 56,421. Revenue per visit also rose 4.6% to $152.67. This combination of higher activity and increased revenue per visit directly contributed to the company's overall revenue growth and improved operating margin, which expanded to approximately 19.0% from 16.3% in Q2 2025.
3. Favorable Analyst Sentiment and Upgraded Price Targets. Analysts reacted positively to Concentra's performance and outlook, with several firms reiterating or upgrading their ratings and price targets. For instance, Truist Financial boosted its price target to $37.00 on July 14, 2026, while Goldman Sachs initiated coverage with a "Buy" rating and a $30.00 price objective on June 5, 2026. William Blair also began coverage with an "Outperform" rating on July 1, 2026. The consensus among nine brokerage firms is a "Moderate Buy" rating for the stock, with an average target price ranging from $31.40 to $34.00, reflecting optimism for continued upside.
Show less
Stock Movement Drivers
Fundamental Drivers
The 52.1% change in CON stock from 4/30/2026 to 8/10/2026 was primarily driven by a 25.2% change in the company's P/E Multiple.| (LTM values as of) | 4302026 | 8102026 | Change |
|---|---|---|---|
| Stock Price ($) | 22.42 | 34.10 | 52.1% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2,163 | 2,287 | 5.7% |
| Net Income Margin (%) | 7.7% | 8.7% | 12.9% |
| P/E Multiple | 17.2 | 21.5 | 25.2% |
| Shares Outstanding (Mil) | 128 | 125 | 1.8% |
| Cumulative Contribution | 52.1% |
Market Drivers
4/30/2026 to 8/10/2026| Return | Correlation | |
|---|---|---|
| CON | 52.1% | |
| Market (SPY) | 7.6% | 2.5% |
| Sector (XLV) | 15.4% | 28.0% |
Fundamental Drivers
The 54.5% change in CON stock from 1/31/2026 to 8/10/2026 was primarily driven by a 18.5% change in the company's Net Income Margin (%).| (LTM values as of) | 1312026 | 8102026 | Change |
|---|---|---|---|
| Stock Price ($) | 22.07 | 34.10 | 54.5% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2,089 | 2,287 | 9.5% |
| Net Income Margin (%) | 7.3% | 8.7% | 18.5% |
| P/E Multiple | 18.5 | 21.5 | 16.5% |
| Shares Outstanding (Mil) | 128 | 125 | 2.3% |
| Cumulative Contribution | 54.5% |
Market Drivers
1/31/2026 to 8/10/2026| Return | Correlation | |
|---|---|---|
| CON | 54.5% | |
| Market (SPY) | 12.0% | 18.3% |
| Sector (XLV) | 9.3% | 32.7% |
Fundamental Drivers
The 72.6% change in CON stock from 7/31/2025 to 8/10/2026 was primarily driven by a 34.6% change in the company's P/E Multiple.| (LTM values as of) | 7312025 | 8102026 | Change |
|---|---|---|---|
| Stock Price ($) | 19.75 | 34.10 | 72.6% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1,933 | 2,287 | 18.3% |
| Net Income Margin (%) | 8.1% | 8.7% | 7.3% |
| P/E Multiple | 16.0 | 21.5 | 34.6% |
| Shares Outstanding (Mil) | 127 | 125 | 1.0% |
| Cumulative Contribution | 72.6% |
Market Drivers
7/31/2025 to 8/10/2026| Return | Correlation | |
|---|---|---|
| CON | 72.6% | |
| Market (SPY) | 23.3% | 21.6% |
| Sector (XLV) | 30.8% | 32.6% |
Fundamental Drivers
nullnull
Market Drivers
7/31/2023 to 8/10/2026| Return | Correlation | |
|---|---|---|
| CON | ||
| Market (SPY) | 74.8% | 36.9% |
| Sector (XLV) | 31.5% | 40.3% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| CON Return | - | - | - | -12% | 1% | 74% | 55% |
| Peers Return | 30% | 3% | -8% | 0% | 20% | 21% | 78% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 13% | 107% |
Monthly Win Rates [3] | |||||||
| CON Win Rate | - | - | - | 50% | 33% | 88% | |
| Peers Win Rate | 60% | 52% | 40% | 52% | 62% | 65% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 50% | |
Max Drawdowns [4] | |||||||
| CON Max Drawdown | - | - | - | - | -21% | -13% | |
| Peers Max Drawdown | -21% | -24% | -26% | -22% | -21% | -16% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: ADUS, CVS, CI, DGX, LH.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 8/10/2026 (YTD)
How Low Can It Go
| Event | CON | S&P 500 |
|---|---|---|
| 2025 US Tariff Shock | ||
| % Loss | -14.8% | -18.8% |
| % Gain to Breakeven | 17.4% | 23.1% |
| Time to Breakeven | 128 days | 79 days |
In The Past
Concentra Parent's stock fell -14.8% during the 2025 US Tariff Shock. Such a loss loss requires a 17.4% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
In The Past
Concentra Parent's stock fell -14.8% during the 2025 US Tariff Shock. Such a loss loss requires a 17.4% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Concentra Parent (CON)
Concentra Parent (CON) is the largest provider of occupational health services in the United States, operating 547 stand-alone health centers, 151 onsite health clinics, and a telemedicine program across 45 states and the District of Columbia. The company's core mission is to enhance the health of America's workforce, serving approximately 50,000 patients daily. Its primary customers are employers across the U.S., including 100% of Fortune 100 and 95% of Fortune 500 companies, utilizing Concentra's services for employees in various industries such as transportation, manufacturing, and construction.
The majority of Concentra's revenue (approximately 95%) comes from its Occupational Health Centers segment. Here, it offers a comprehensive suite of services, prominently including workers' compensation injury and physical rehabilitation care, which accounts for about 64% of visit-related revenue in this segment. Additional services include employer-focused offerings like drug and alcohol screenings, physical examinations, and preventive care (about 34% of revenue), along with a smaller segment of consumer health services. The company's value proposition is centered on a methodology of early intervention and expedited return to work, aiming to improve health outcomes, reduce employee time away, and lower overall workers' compensation costs for employers. Studies suggest Concentra's approach leads to significantly lower average total claims costs and reduced claim durations compared to non-Concentra facilities.
Concentra maintains a dominant market position, estimating it supported the treatment of one in every five workplace injuries in the U.S. in 2022, with a national presence ensuring accessibility for a vast number of employer locations. The company has a strong track record of financial performance and aims for continued growth through expanding its existing centers, pursuing strategic acquisitions, opening new facilities in key markets, and developing adjacent service offerings. These planned expansions include advanced primary care solutions for employers and behavioral health workers' compensation capabilities, underscoring its commitment to innovation and long-term sustainable growth.
AI Analysis | Feedback
Here are 1-3 brief analogies to describe Concentra Parent:
Think of Concentra as the 'MinuteClinic for the workplace' – a national network of clinics providing specialized care for employee injuries and other employer health services, helping businesses reduce workers' compensation costs.
It's like a national urgent care chain (e.g., MedExpress or AFC Urgent Care), but exclusively dedicated to occupational health, worker's compensation, and direct employer services rather than general consumer illness.
AI Analysis | Feedback
- Workers' Compensation Services: Provides comprehensive medical treatment and physical rehabilitation for workplace injuries and illnesses.
- Employer Services: Offers a suite of direct-to-employer solutions, including drug and alcohol screenings, physical examinations, clinical testing, preventive care, and advanced primary care.
- Consumer Health Services: Delivers patient-directed urgent care for minor injuries and illnesses.
- Telemedicine Services: Provides remote occupational health and related services through virtual platforms.
- Pharmacy Services: Offers pharmacy solutions, likely related to occupational health and employee well-being.
- Medical Compliance Administration: Assists employers with managing medical regulatory compliance requirements.
AI Analysis | Feedback
- By Size: They serve all types of employers, ranging from small businesses to medium, large, Fortune 500, and Fortune 100 corporations.
- By Industry: Their services are utilized by employers across diverse industries, including transportation, distribution and warehousing, manufacturing, construction, healthcare, and municipal government services, among many others.
AI Analysis | Feedback
AI Analysis | Feedback
William Keith Newton, Chief Executive Officer
Mr. Newton has served as Chief Executive Officer of Concentra since rejoining in 2015 and as President until 2023. He was previously President and Chief Operating Officer of Concentra from 2007 to 2011. Between 2011 and 2015, Mr. Newton was President and Chief Executive Officer of DentalOne Partners. He also directed operations for OccuSystems, Inc. from 1995 to 1999, one of the companies that merged to form Concentra in 1997. From 1999 to 2007, he served as president of Concentra's former Health Services division. Prior to 1995, Mr. Newton worked for Columbia HCA's Ambulatory Surgery Division and its predecessor Medical Care International.
Matthew T. DiCanio, President & Chief Financial Officer
Mr. DiCanio has served as President since 2023 and Chief Financial Officer since 2024. He oversees Concentra's financial operations, strategic financial planning, investment activities, growth initiatives, mergers and acquisitions, and real estate activities. He was previously responsible for the Valor Healthcare outpatient division (since divested). Before joining Concentra, Mr. DiCanio held various positions in finance, mergers and acquisitions, and management, including serving as principal and co-head of the healthcare vertical at a middle-market investment bank and as an investment banker with Bank of America Merrill Lynch. He is also a CPA.
Michael D. Rhine, Executive Vice President, Chief Operating Officer of Onsite Health & Telemedicine
Mr. Rhine is responsible for the strategic leadership and operational management of Concentra's onsite health services and telemedicine programs. He focuses on optimizing the delivery of care through these channels, ensuring efficiency, quality, and accessibility for patients.
Michael A. Kosuth, Executive Vice President & Chief Operating Officer of East
Mr. Kosuth oversees the day-to-day operations of over 280 medical centers in Concentra's eastern region. He manages and optimizes field operations, with responsibility for the profit and loss (P&L) of the centers. He joined Concentra in 1996 in an operational development role and has held various positions, applying his leadership to drive the company forward.
Jonathan P. Conser, Executive Vice President and Chief Growth & Customer Officer
Mr. Conser is responsible for driving Concentra's growth initiatives and fostering strong customer relationships. He leads efforts in customer acquisition, revenue operations, and relationship management, including field sales, key accounts, strategic national accounts, payor relationships, employer services TPA, telemedicine, and network channel relationships. He has served in various key sales management roles since joining Concentra in 2003.
AI Analysis | Feedback
Key Business Risks for Concentra Parent (CON)
- Dependence on Demand for Workers' Compensation and Employer Services: Concentra's business is heavily reliant on providing occupational health services, primarily workers' compensation and employer services, to its extensive network of employer customers. For the three months ended March 31, 2024, these services represented approximately 98% of visit-related revenue in the Occupational Health Centers segment. The utilization of Concentra's services is largely driven by occupations with a higher-than-average risk of workplace injury and illness. Consequently, the company is susceptible to external factors such as economic downturns that could reduce employment levels, advancements in workplace safety that might decrease injury rates, or significant changes in workers' compensation laws and regulations that could alter employer demand or reimbursement structures.
- Competition in the Occupational Health Market: Although Concentra emphasizes its competitive advantages through clinical outcomes and patient satisfaction, the company operates within a competitive landscape. Its own studies on workers' compensation claims indicate that "non-Concentra health centers" accounted for a substantial portion of the evaluated claims, suggesting that employers have alternative providers for occupational injury treatment. The ability to continuously retain existing employer relationships and attract new ones is crucial, implying an ongoing risk from competitors seeking to capture market share.
- Risks Related to Growth Through Acquisitions and New Center Development: Concentra's strategy for continued growth includes pursuing strategic acquisitions and opening new occupational health centers in key markets. While these initiatives aim to expand the company's footprint and customer base, they inherently carry risks. These include challenges in successfully integrating acquired businesses, higher-than-anticipated operational or capital expenditures, difficulties in achieving expected synergies, and potential issues with market acceptance or regulatory hurdles for new facilities.
AI Analysis | Feedback
AI Analysis | Feedback
The addressable market for Concentra Parent's workers' compensation services, specifically related to occupational injuries, is approximately 3.5 million occupational injuries in the U.S. per year.
AI Analysis | Feedback
Concentra Parent (CON) is expected to drive future revenue growth over the next 2-3 years through several key strategies:
- Organic Growth and Customer Expansion: The company plans to pursue continued organic growth within its existing occupational health centers and onsite health clinics. This involves increasing patient volume and attracting new employers by demonstrating strong clinical outcomes and patient satisfaction.
- Expansion of Physical Footprint: Concentra intends to grow its presence by opening new occupational health centers in key markets.
- Strategic Acquisitions: The company will leverage strategic acquisitions to expand its footprint and customer base.
- Introduction and Expansion of New Service Offerings: Concentra is actively building out adjacent service offerings. These include employer-focused advanced primary care solutions, behavioral health workers’ compensation capabilities, growth of its specialist program, and the expansion of mobile health and episodic specialty testing services.
AI Analysis | Feedback
Share Repurchases
- Concentra repurchased approximately 1.1 million shares of common stock totaling $22.4 million in 2025.
- The company authorized a share repurchase program for up to $100 million of common stock, with $80 million remaining as of year-end 2025.
- Concentra intends to continue opportunistically executing its share repurchase program in 2026.
Share Issuance
- On July 26, 2024, Concentra completed its Initial Public Offering (IPO), issuing 22,500,000 shares of common stock at a price of $23.50 per share, generating gross proceeds of $528.8 million.
- The 2024 Equity Incentive Plan authorized the issuance of 5,925,000 shares of common stock, with approximately 3,108,014 shares issued through December 31, 2025.
Inbound Investments
- Prior to its IPO in July 2024, Concentra was a wholly-owned subsidiary of Select Medical Holdings Corporation.
- In connection with its spin-off and IPO, Concentra planned to issue approximately $750 million of secured debt and $750 million of unsecured debt, distributing the proceeds to Select Medical and retaining about $100 million in cash for general corporate purposes.
Outbound Investments
- In 2025, Concentra executed strategic acquisitions, including Nova Medical Centers ("Nova") and Pivot Onsite Innovations, to expand its occupational health centers and onsite health clinics.
- These acquisitions were financed using a combination of new debt, existing credit facilities, and cash on hand.
Capital Expenditures
- Capital expenditures for the full year 2025 were $82.3 million, an increase of 28.0% from $64.3 million in 2024. These included approximately $15 million in one-time transition costs related to the Nova acquisition.
- For the fourth quarter of 2025, capital expenditures amounted to $20.2 million, with approximately $4 million attributed to one-time Nova acquisition transition costs.
- For the full year 2026, Concentra anticipates capital expenditures to be in the range of $70 million to $80 million, primarily focused on investments in new centers ("de novos"), relocations, renovations, maintenance, and IT.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| How Low Can Concentra Parent Stock Really Go? | 10/17/2025 | |
| Concentra Parent (CON) Valuation Ratios Comparison | 05/15/2025 | |
| Concentra Parent (CON) Operating Cash Flow Comparison | 02/17/2025 | |
| Concentra Parent (CON) Net Income Comparison | 02/15/2025 | |
| Concentra Parent (CON) Operating Income Comparison | 02/14/2025 | |
| Concentra Parent (CON) Revenue Comparison | 02/13/2025 | |
| ARTICLES | ||
| Small Cap Stocks Trading At 52-Week High | 06/21/2026 |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 178.49 |
| Mkt Cap | 26.3 |
| Rev LTM | 12,954 |
| Op Inc LTM | 1,632 |
| FCF LTM | 1,252 |
| FCF 3Y Avg | 1,120 |
| CFO LTM | 1,771 |
| CFO 3Y Avg | 1,591 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 8.8% |
| Rev Chg 3Y Avg | 7.0% |
| Rev Chg Q | 7.6% |
| QoQ Delta Rev Chg LTM | 1.8% |
| Op Inc Chg LTM | 23.2% |
| Op Inc Chg 3Y Avg | 11.6% |
| Op Mgn LTM | 10.7% |
| Op Mgn 3Y Avg | 9.6% |
| QoQ Delta Op Mgn LTM | 0.2% |
| CFO/Rev LTM | 11.2% |
| CFO/Rev 3Y Avg | 10.6% |
| FCF/Rev LTM | 9.3% |
| FCF/Rev 3Y Avg | 8.5% |
Segment Financials
Revenue by Segment| $ Mil | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Single Segment | 2,163 | 1,900 | 1,838 | ||
| Occupational health centers | 1,630 | 1,550 | |||
| Onsite health clinics | 56 | 145 | |||
| Other | 38 | 38 | |||
| Total | 2,163 | 1,900 | 1,838 | 1,724 | 1,732 |
| $ Mil | 2025 | 2024 | 2023 |
|---|---|---|---|
| Single Segment | 432 | 377 | 361 |
| Separation transaction costs | -4 | -2 | 0 |
| Nova and Pivot Onsite Innovations acquisition costs | -7 | -1 | 0 |
| Stock compensation expense | -10 | -2 | -1 |
| Depreciation and amortization | -76 | -67 | -73 |
| Total | 334 | 305 | 288 |
| $ Mil | 2025 | 2024 | 2023 |
|---|---|---|---|
| Single Segment | 2,858 | 2,521 | 2,334 |
| Total | 2,858 | 2,521 | 2,334 |
Price Behavior
| Market Price | $34.10 | |
| Market Cap ($ Bil) | 4.3 | |
| First Trading Date | 07/25/2024 | |
| Distance from 52W High | 0.0% | |
| 50 Days | 200 Days | |
| DMA Price | $29.78 | $23.72 |
| DMA Trend | up | up |
| Distance from DMA | 14.5% | 43.8% |
| 3M | 1YR | |
| Volatility | 32.8% | 28.4% |
| Downside Capture | -65.83 | 13.38 |
| Upside Capture | 83.14 | 63.67 |
| Correlation (SPY) | 3.9% | 20.6% |
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.27 | -0.01 | 0.02 | 0.35 | 0.49 | -0.05 |
| Up Beta | -0.32 | -0.26 | -0.21 | 0.54 | 0.68 | 0.30 |
| Down Beta | 1.95 | 0.37 | 0.62 | 0.78 | 0.53 | 0.25 |
| Up Capture | 40% | 74% | 71% | 52% | 54% | 16% |
| Bmk +ve Days | 11 | 22 | 35 | 67 | 138 | 427 |
| Stock +ve Days | 11 | 26 | 39 | 69 | 128 | 249 |
| Down Capture | -58% | -93% | -114% | -36% | 20% | 63% |
| Bmk -ve Days | 11 | 21 | 28 | 59 | 114 | 326 |
| Stock -ve Days | 11 | 17 | 23 | 54 | 120 | 252 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CON | |
|---|---|---|---|---|
| CON | 71.0% | 29.1% | 1.84 | - |
| Sector ETF (XLV) | 32.4% | 15.6% | 1.60 | 33.5% |
| Equity (SPY) | 23.4% | 12.8% | 1.37 | 20.3% |
| Gold (GLD) | 28.7% | 28.4% | 0.88 | 3.9% |
| Commodities (DBC) | 37.2% | 20.1% | 1.46 | -17.5% |
| Real Estate (VNQ) | 12.4% | 13.8% | 0.60 | 32.8% |
| Bitcoin (BTCUSD) | -44.9% | 43.0% | -1.27 | 1.6% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CON | |
|---|---|---|---|---|
| CON | 9.1% | 30.5% | 0.72 | - |
| Sector ETF (XLV) | 6.6% | 15.0% | 0.25 | 40.3% |
| Equity (SPY) | 13.5% | 17.2% | 0.61 | 36.9% |
| Gold (GLD) | 18.9% | 18.6% | 0.83 | 4.5% |
| Commodities (DBC) | 9.2% | 19.6% | 0.36 | -4.2% |
| Real Estate (VNQ) | 2.1% | 18.9% | 0.01 | 42.6% |
| Bitcoin (BTCUSD) | 10.6% | 52.9% | 0.39 | 9.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with CON | |
|---|---|---|---|---|
| CON | 4.5% | 30.5% | 0.72 | - |
| Sector ETF (XLV) | 10.2% | 16.6% | 0.50 | 40.3% |
| Equity (SPY) | 15.4% | 17.9% | 0.73 | 36.9% |
| Gold (GLD) | 12.1% | 16.2% | 0.61 | 4.5% |
| Commodities (DBC) | 7.7% | 18.1% | 0.34 | -4.2% |
| Real Estate (VNQ) | 4.6% | 20.7% | 0.18 | 42.6% |
| Bitcoin (BTCUSD) | 58.3% | 66.2% | 0.98 | 9.8% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 6/10/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/7/2026 | 2.4% | 11.0% | 8.1% |
| 2/26/2026 | 1.4% | -0.8% | -10.4% |
| 11/6/2025 | 3.4% | 5.6% | 4.0% |
| 8/7/2025 | 7.0% | 15.8% | 12.9% |
| 5/7/2025 | -3.5% | -2.3% | 1.0% |
| 3/3/2025 | 0.3% | -3.5% | -1.3% |
| 10/31/2024 | -0.9% | -1.1% | 6.5% |
| 8/1/2024 | -0.0% | 1.9% | 7.9% |
| SUMMARY STATS | |||
| # Positive | 5 | 4 | 6 |
| # Negative | 3 | 4 | 2 |
| Median Positive | 2.4% | 8.3% | 7.2% |
| Median Negative | -0.9% | -1.7% | -5.9% |
| Max Positive | 7.0% | 15.8% | 12.9% |
| Max Negative | -3.5% | -3.5% | -10.4% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 5/7/2026 | 2.4% | 11.0% | 8.1% |
| 2/26/2026 | 1.4% | -0.8% | -10.4% |
| 11/6/2025 | 3.4% | 5.6% | 4.0% |
| 8/7/2025 | 7.0% | 15.8% | 12.9% |
| 5/7/2025 | -3.5% | -2.3% | 1.0% |
| 3/3/2025 | 0.3% | -3.5% | -1.3% |
| 10/31/2024 | -0.9% | -1.1% | 6.5% |
| 8/1/2024 | -0.0% | 1.9% | 7.9% |
| SUMMARY STATS | |||
| # Positive | 5 | 4 | 6 |
| # Negative | 3 | 4 | 2 |
| Median Positive | 2.4% | 8.3% | 7.2% |
| Median Negative | -0.9% | -1.7% | -5.9% |
| Max Positive | 7.0% | 15.8% | 12.9% |
| Max Negative | -3.5% | -3.5% | -10.4% |
Recent Forward Guidance
Updated 7/27/2026Latest: Q1 2026 Earnings Reported 5/7/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | 2.27 Bil | 2.33 Bil | 2.38 Bil | 1.1% | Raised | Guidance: 2.30 Bil for 2026 | |
| 2026 Adjusted EBITDA | 460.00 Mil | 470.00 Mil | 480.00 Mil | 2.2% | Raised | Guidance: 460.00 Mil for 2026 | |
| 2026 Net leverage ratio | 3 | 0 | Affirmed | Guidance: 3 for 2026 | |||
| 2026 Free Cash Flow | 215.00 Mil | 225.00 Mil | 235.00 Mil | 5.9% | Raised | Guidance: 212.50 Mil for 2026 | |
| 2026 Capital expenditures | 70.00 Mil | 75.00 Mil | 80.00 Mil | 0 | Affirmed | Guidance: 75.00 Mil for 2026 | |
Prior: Q4 2025 Earnings Reported 2/26/2026
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2026 Revenue | 2.25 Bil | 2.30 Bil | 2.35 Bil | ||||
| 2026 Adjusted EBITDA | 450.00 Mil | 460.00 Mil | 470.00 Mil | ||||
| 2026 Net leverage ratio | 3 | 3 | 0.0% | Affirmed | Guidance: 3 for 2026 | ||
| 2026 Free Cash Flow | 200.00 Mil | 212.50 Mil | 225.00 Mil | ||||
| 2026 Capital expenditures | 70.00 Mil | 75.00 Mil | 80.00 Mil | ||||
Q3 2025 Earnings Reported 11/6/2025
| Forward Guidance | Guidance Change | ||||||
|---|---|---|---|---|---|---|---|
| Metric | Low | Mid | High | % Chg | % Delta | Change | Prior |
| 2025 Revenue | 2.15 Bil | 2.15 Bil | 2.16 Bil | 0.3% | Raised | Guidance: 2.15 Bil for 2025 | |
| 2025 Adjusted EBITDA | 425.00 Mil | 427.50 Mil | 430.00 Mil | 0.6% | Raised | Guidance: 425.00 Mil for 2025 | |
| 2025 Capital Expenditures | 80.00 Mil | 85.00 Mil | 90.00 Mil | 0 | Affirmed | Guidance: 85.00 Mil for 2025 | |
| 2025 Net Leverage Ratio | 3.5 | 0 | Affirmed | Guidance: 3.5 for 2025 | |||
| 2026 Net Leverage Ratio | 3 | 0 | Affirmed | Guidance: 3 for 2026 | |||
Insider Activity
Updated 8/5/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Ortenzio, Robert A | The Rocco A. Ortenzio Separate Descendants Trust FBO Robert Ortenzio | Sell | 8052026 | 31.84 | 130,000 | 4,139,356 | 16,030,611 | Form | |
| 2 | Ortenzio, Robert A | The Rocco A. Ortenzio Separate Descendants Trust FBO Robert Ortenzio | Sell | 7062026 | 30.50 | 130,000 | 3,964,597 | 19,318,414 | Form | |
| 3 | Ortenzio, Robert A | The Rocco A. Ortenzio Separate Descendants Trust FBO Robert Ortenzio | Sell | 6022026 | 25.00 | 130,000 | 3,250,026 | 19,086,528 | Form | |
| 4 | Ortenzio, Robert A | The Rocco A. Ortenzio Separate Descendants Trust FBO Robert Ortenzio | Sell | 5112026 | 25.00 | 130,000 | 3,250,000 | 22,336,375 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Ortenzio, Robert A | The Rocco A. Ortenzio Separate Descendants Trust FBO Robert Ortenzio | Sell | 8052026 | 31.84 | 130,000 | 4,139,356 | 16,030,611 | Form | |
| 2 | Ortenzio, Robert A | The Rocco A. Ortenzio Separate Descendants Trust FBO Robert Ortenzio | Sell | 7062026 | 30.50 | 130,000 | 3,964,597 | 19,318,414 | Form | |
| 3 | Ortenzio, Robert A | The Rocco A. Ortenzio Separate Descendants Trust FBO Robert Ortenzio | Sell | 6022026 | 25.00 | 130,000 | 3,250,026 | 19,086,528 | Form | |
| 4 | Ortenzio, Robert A | The Rocco A. Ortenzio Separate Descendants Trust FBO Robert Ortenzio | Sell | 5112026 | 25.00 | 130,000 | 3,250,000 | 22,336,375 | Form |
Investor Activity (13F)
Updated Aug 11, 2026Active managers (13F portfolio over $250M, at least 3 holdings) with a position over $5M that is either over 10% of their portfolio or held in a concentrated book of 50 or fewer total positions. Index/ETF, sovereign, bank, community-bank and charitable/donor-advised filers are excluded.
| Active Manager |
|---|
Industry Resources
| Health Care Resources |
| U.S. National Library of Medicine |
| ClinicalTrials.gov |
| Modern Healthcare |
| Healthcare Dive |
| Fierce Healthcare |
| Health Affairs |
| Health Data Management |
| FDA Tracker |
| Health Care Services Resources |
| HealthLeaders Media |
| Medical Economics |
| Physicians Practice |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.